Patents by Inventor MICHAEL T. BETHUNE

MICHAEL T. BETHUNE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition of NY-ESO-1-specific t cell receptors restricted on multiple major histocompatibility complex molecules
    Patent number: 12617834
    Abstract: Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: May 5, 2026
    Assignees: THE REGENT'S OF THE UNIVERSITY OF CALIFORNIA, CALIFORNIA INSTITUTE OF TECHNOLOGY, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
    Inventors: Owen N. Witte, Jami McLaughlin Witte, Antoni Ribas, Lili Yang, Michael T. Bethune, Jonathan Cebon, Katherine Woods, Ashley J. Knights, David Baltimore
  • Trogocytosis mediated epitope discovery methods
    Patent number: 12066430
    Abstract: Disclosed herein are trogocytosis based TCR ligand discovery platforms and methods of using the same, trogocytosis based TCR discovery platforms and methods of using the same, and trogocytosis based ligand discovery platforms and methods of using the same. Also disclosed herein are isolated cells, nucleotides, sequences, and sequence databases produced using trogocytosis based discovery platforms.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: August 20, 2024
    Assignee: California Institute of Technology
    Inventors: Michael T. Bethune, Jocelyn T. Kim, David Baltimore, Guideng Li, Stephanie Wong
  • COMPOSITION OF NY-ESO-1-SPECIFIC T CELL RECEPTORS RESTRICTED ON MULTIPLE MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES
    Publication number: 20210324035
    Abstract: Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.
    Type: Application
    Filed: September 4, 2019
    Publication date: October 21, 2021
    Applicants: The Regents of the University of California, California Institute of Technology, The Olivia Newton-John Cancer Research Institute
    Inventors: Owen N. Witte, Jami McLaughlin Witte, Antoni Ribas, Lili Yang, Michael T. Bethune, Jonathan Cebon, Katherine Woods, Ashley J. Knights, David Baltimore
  • TROGOCYTOSIS MEDIATED EPITOPE DISCOVERY
    Publication number: 20200309765
    Abstract: Disclosed herein are trogocytosis based TCR ligand discovery platforms and methods of using the same, trogocytosis based TCR discovery platforms and methods of using the same, and trogocytosis based ligand discovery platforms and methods of using the same. Also disclosed herein are isolated cells, nucleotides, sequences, and sequence databases produced using trogocytosis based discovery platforms.
    Type: Application
    Filed: July 24, 2018
    Publication date: October 1, 2020
    Inventors: Michael T. Bethune, Jocelyn T. Kim, David Baltimore, Guideng Li, Stephanie Wong
  • Domain-swap T cell receptors
    Patent number: 9884075
    Abstract: Disclosed herein are genetically engineered T cell receptors, and methods, vectors, and genetically engineered T cells related to genetically engineered T cell receptors.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: February 6, 2018
    Assignee: California Institute of Technology
    Inventors: Michael T. Bethune, Marvin H. Gee, David Baltimore
  • DOMAIN-SWAP T CELL RECEPTORS
    Publication number: 20150197771
    Abstract: Disclosed herein are genetically engineered T cell receptors, and methods, vectors, and genetically engineered T cells related to genetically engineered T cell receptors.
    Type: Application
    Filed: January 15, 2015
    Publication date: July 16, 2015
    Inventors: MICHAEL T. BETHUNE, MARVIN H. GEE, DAVID BALTIMORE